Maurie Markman, MD

Articles

Dr. Markman on Precision Medicine in Ovarian Cancer

November 30th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the impact of precision medicine in ovarian cancer.

Dr. Markman on the Concept of Biosimilars in Oncology

November 27th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care® for Gynecological Cancers, discusses the concept of biosimilars in oncology.

Single Versus Multiagent Therapy: It's Time to Revisit the Choices

November 22nd 2018

Maurie Markman, MD discusses the importance of objective evidence when using a combination approach as opposed to a single-agent treatment.

Dr. Markman Discusses the Future of Treatment for Ovarian Cancer

November 15th 2018

New Tools Needed to Manage Toxicities in Modern Era of Cancer Therapy

November 2nd 2018

Maurie Markman, MD, discusses the search for less toxic strategies for the treatment of cancer that may lessen the negative impact on quality of life while maintaining therapeutic efficacy.

Genetic Revolution Should Not Overlook Privacy Concerns

October 15th 2018

Maurie Markman, MD, discusses privacy concerns associated with genetic testing.

Early-Stage Oncology Trials Increasingly Yield Therapeutic Benefits

September 29th 2018

Maurie Markman, MD, discusses the clinical benefit of early-stage trials.

Great Advances Call for Great Vigilance and Integrity

September 24th 2018

Maurie Markman, MD, reflects on how technological advances have impacted translational science and clinical medicine.

Surgical Trials Highlight Complexity of Interpreting Randomized Data

August 31st 2018

In recent years there has been much discussion about the serious limitations of the conduct and interpretation of randomized trials examining the utility of antineoplastic drug therapy.

Patient-Experienced Toxicity Is a Biomarker Worth Considering

August 17th 2018

Maurie Markman, MD, says that the acceleration in regulatory agency approvals for novel antineoplastic agents and the focus of biomarker discovery proves that this is the era of precision medicine.

Reforms Would Add Value to the Randomized Trial

July 30th 2018

Maurie Markman, MD, discusses the increasing criticism of the phase III randomized trial in oncology.

Dr. Markman on Latest Advances in Treatment of Gynecological Malignancies

July 18th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Defining Precision Cancer Medicine the Right Way

July 17th 2018

Maurie Markman, MD, defines precision medicine in oncology.

Inaccurate, Muddled Messages Jeopardize the Public's Trust in Science

June 27th 2018

The public’s faith in science, particularly in efforts related to health, is crucial for the successful implementation of strategies designed to improve the human condition, says Maurie Markman, MD.

Genetic Cancer Risk Assessment: Highly Relevant But Increasingly Complex

June 12th 2018

Maurie Markman, MD, discusses the potential to employ germline data and knowledge about the presence of specific common, uncommon, or rare variants to cancer therapy.

Will Precision Medicine Displace the Randomized Trial?

May 20th 2018

Maurie Markman, MD, sheds light on the debate regarding the future direction of clinical investigation.

Right-to-Try Laws: Let's Move Beyond the Rhetoric

May 15th 2018

Maurie Markman, MD, shares his thoughts on the right-to-try bill, which would allow terminally ill patients to receive investigational drugs that have been studied in phase I trials without applying through the FDA’s expanded access program.

Opioid Epidemic Poses Complex Problem for Cancer Care

May 10th 2018

Maurie Markman, MD, discusses the cause and impact of the opioid addiction epidemic in the United States.

All Is Not Well in the World of Academic Scientific Enterprise

April 28th 2018

It is quite difficult for those not directly involved in the complex world of academic medicine to understand fully the process of individual professional advancement and the values that organizations place on the components required for achieving and maintaining tenure.

HPV Vaccination Should Be Part of Oncology Cost-Reduction Strategy

April 3rd 2018

The impact of staggering increases in the cost of individual antineoplastic agents for patients and the overall healthcare system cannot be overstated, and there appears to be no realistic solution to the current dilemma that is acceptable to the parties involved in this ongoing debate.